(Q43582639)

24 November 2017

title

Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

24 November 2017

1 reference

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24356885%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Moti L Kashyap

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24356885%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

author name string

Shobha H Ganji

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24356885%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Gary D Kukes

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24356885%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Vaijinath S Kamanna

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24356885%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

publication date

19 December 2013

1 reference

American Journal of Physiology - Gastrointestinal and Liver Physiology

24 November 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24356885%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

volume

306

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24356885%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24356885%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

G320-7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24356885%20AND%20SRC:MED&resulttype=core&format=json

Nonalcoholic fatty liver disease as a complication of insulin resistance

12 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00181.2013

Treatment of non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00181.2013

Current treatment of non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00181.2013

Nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00181.2013

Mouse models in non-alcoholic fatty liver disease and steatohepatitis research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00181.2013

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00181.2013

A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00181.2013

Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00181.2013

Hepatic steatosis: innocent bystander or guilty party?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00181.2013

Steatohepatitis: a tale of two "hits"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00181.2013

Steatohepatitis induced by intragastric overfeeding in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00181.2013

The price of innovation: new estimates of drug development costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00181.2013

Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00181.2013

Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00181.2013

Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00181.2013

Liver fat reduction with niacin is influenced by DGAT-2 polymorphisms in hypertriglyceridemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00181.2013

Mechanism of action of niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00181.2013

Niacin therapy in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00181.2013

Nonalcoholic fatty liver disease and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00181.2013

Dissociation of Hepatic Steatosis and Insulin Resistance in Mice Overexpressing DGAT in the Liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00181.2013

Altered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00181.2013

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00181.2013

Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00181.2013

Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00181.2013

Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00181.2013

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00181.2013

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00181.2013

Animal models of non-alcoholic steatohepatitis: of mice and man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00181.2013

Therapeutic effects of restricted diet and exercise in obese patients with fatty liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00181.2013

Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00181.2013

Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00181.2013

21 January 2018

Identifiers

DOI

10.1152/AJPGI.00181.2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24356885%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference